Baseline ECG Before Starting Lithium
A baseline ECG should be obtained before initiating lithium therapy, particularly in patients over 50 years of age, those with known or suspected cardiac disease, or those with pre-existing ECG abnormalities. 1
Risk Stratification for Baseline ECG
The decision to obtain a baseline ECG depends on clinical risk factors:
High-Priority Patients (ECG Mandatory)
- Age >50 years - ECG abnormalities are significantly more prevalent in this population, with approximately half of abnormal tracings occurring in patients over 50 2
- Known cardiovascular disease - Including ischemic heart disease, heart failure, or structural heart abnormalities 3
- Pre-existing conduction abnormalities - Particularly patients with suspected Brugada pattern (types 2 or 3), as lithium can unmask type 1 Brugada pattern even at therapeutic levels 1
- Concurrent QT-prolonging medications - Lithium has divergent reports regarding QT prolongation but can cause bradycardia, T wave changes, and AV blocks 4
- Renal impairment or electrolyte disturbances - These conditions increase lithium toxicity risk and cardiac complications 3
Lower-Priority Patients (Clinical Judgment)
For patients under 50 years without cardiac risk factors, routine screening ECG yields relatively few abnormalities 2. However, obtaining a baseline remains prudent for future comparison if cardiac symptoms develop.
Repeat ECG Monitoring Indications
Routine ECG monitoring during stable lithium therapy is not necessary in asymptomatic patients with therapeutic lithium levels and no cardiac symptoms 5. However, repeat ECG is indicated when:
Specific Triggers for Repeat ECG
- Development of cardiac symptoms - Palpitations, syncope, chest pain, or dyspnea
- Lithium toxicity or over-range levels (>1.2 mEq/L) - QTc >440 ms and diffuse T wave inversion are highly predictive of lithium over-range (64% sensitivity, 97% specificity when combined) 6
- Addition of other QT-prolonging medications - Consider alternative non-QT-prolonging drugs when possible rather than just monitoring 7
- Electrolyte disturbances - Particularly hypokalemia or changes in renal function 7
- Dose escalation in high-risk patients - Similar to methadone protocols, though less stringent 4
Common ECG Changes with Lithium
Understanding expected ECG changes helps distinguish benign from concerning findings:
- Most common: T wave flattening or inversion (benign at therapeutic levels) 8, 5
- Conduction changes: Slight PR prolongation, sinus bradycardia 5
- Concerning findings: QTc >440 ms, diffuse T wave inversion (suggests over-range), heart blocks, ventricular arrhythmias, Brugada pattern 1, 6, 8
Critical Pitfalls to Avoid
Do not assume lithium is safe simply because levels are therapeutic - Serious cardiac outcomes including Brugada pattern, heart blocks, and STEMI have occurred at therapeutic lithium levels 1, 8. The duration of treatment and cumulative exposure also influence cardiac effects, independent of current serum levels 8.
Obtain baseline ECG before starting lithium in any patient with type 2 or 3 Brugada pattern - Lithium can convert these to type 1 pattern, increasing sudden cardiac death risk. Discontinuation typically resolves the pattern within 10 days 1.